Drugs / NBP607-QIV
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03826719 | Feb → Mar 2014 | influenza | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT03704740 | Oct 2018 → Jul 2019 | influenza | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03020628 | Oct 2016 → Mar 2017 | influenza | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02467842 | Oct → Dec 2014 | influenza | SK Chemicals Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT02621164 | Sep 2014 → Feb 2015 | influenza | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBP607-QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03020628 ↗ |
| Modality | Vaccine | “cell culture-derived quadrivalent inactivated influenza vaccine (NBP607-QIV)” PMID 28406746 ↗ Apr 2017 |
| Route | Intramuscular | “Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains;...” NCT02467842 ↗ |